Information Provided By: 
Fly News Breaks for December 7, 2016
HZNP
Dec 7, 2016 | 08:33 EDT
JMP Securities analyst Donald Ellis says that the Phase 3 data on Horizon's Actimmune, which he says is due to be released later this month, "should be positive." The analyst predicts that Horizon could generate $500M-$1B from the indication, and he says that the revenue is not included in current Street estimates. He reiterates a $33 price target and an Outperform rating on the shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
